Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 3/20 | 0.38 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.37 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601934 | 0.92 | MEN1 (0.51) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL4603104 | 0.87 | MEN1 (0.53) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL4603545 | 0.87 | MEN1 (0.53) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL4604320 | 0.87 | MEN1 (0.53) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL4603236 | 0.87 | MEN1 (0.53) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL4603335 | 0.87 | MEN1 (0.53) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL4602873 | 0.87 | MEN1 (0.53) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL31229949 | 0.85 | MEN1 (0.61) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL29640487 | 0.85 | MEN1 (0.61) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL8505229 | 0.82 | HTT (0.67) | MEN1THRBHTTKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227865-A1 | COLIPSE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | FORSKARPATENT I SYD AB (SE) | 2008-09-18 | — | — | US | claimed |
| US-7425577-B2 | Lipase-colipase inhibitor | FORSKARPATENT 1 SYD AB (SE) | 2008-09-16 | — | — | US | claimed |
| EP-1660062-B1 | USE OF COLIPASE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | FORSKARPATENT I SYD AB (SE) | 2008-07-09 | — | — | EP | claimed |
| US-20060199869-A1 | Lipase-colipase inhibitor | FORSKARPATENT 1 SYD AB (SE) | 2006-09-07 | — | — | US | claimed |
| US-20080227865-A1 | COLIPSE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | FORSKARPATENT I SYD AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-7425577-B2 | Lipase-colipase inhibitor | FORSKARPATENT 1 SYD AB (SE) | 2008-09-16 | — | — | US | disclosed |
| EP-1660062-B1 | USE OF COLIPASE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | FORSKARPATENT I SYD AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-20060199869-A1 | Lipase-colipase inhibitor | FORSKARPATENT 1 SYD AB (SE) | 2006-09-07 | — | — | US | disclosed |
| EP-1660062-A1 | USE OF COLIPASE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | Forskarpatent i Syd AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005018625-A1 | USE OF COLIPASE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | FORSKARPATENT I SYD AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199869-A1 | Lipase-colipase inhibitor | PNLIP, LPL, LIPC | MEN1 4186/4885THRB 2820/4885HTT 4285/4885 |
| US-20080227865-A1 | COLIPSE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | PNLIP, LIPE, LPL | MEN1 3763/4885THRB 2875/4885HTT 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.